Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0032—Methine dyes, e.g. cyanine dyes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0052—Small organic molecules
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
  • C07F9/572—Five-membered rings
  • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo

Definitions

• the invention generally relates to fluorescent tumor-selective phospholipid ether (PLE) compounds, compositions comprising these compounds, and methods of using these compounds and compositions in various diagnostic applications
• PLE fluorescent tumor-selective phospholipid ether
• Fluorescent imaging has proven to be an efficient tool for preclinical cancer research antitumor drug discovery and pharmacological developments by providing images of the bio-distribution of fluorescent markers By tagging regions of interest with tumor-specific fluorescent molecular probes, this technique enables visualization of location and geometries of malignant areas
• the fundamental barriers to optical imaging in tissue are high light scattering, autofluorescence, and high absorption by hemoglobin in the mid- visible band Use of red and near-infrared light is the most basic step towards improved imaging
• Moving to near-infrared wavelengths (700-1100 nm) confers other advantages for imaging mammalian tissues less background fluorescence is excited, since autofluorescence in tissues is mostly excited by near ultraviolet and blue light, and less autofluorescence interferes, since fluorescence from most mammalian tissues peaks in the yellow and is very low beyond 650nm (Ballou B, Ernst LA, Waggoner AS Curr Med Chem , 2005, 12, 795-805, Fabian J, Nakazumi H, Matsuoka M Chem Rev , 1992, 92 1 197-1226)
• the use of near-IR fluorescence improves in many ways the performance of fluorescence-based biological assays For example, the near- IR fluorescence provides 1) significant reduction of background autofluorescence, 2) deeper light
• Endoscopy in particular, colonoscopy and bronchoscopy, is utilized to find abnormal growth and tumors protruding into the lumen.
• a device called endoscope
• endoscope is inserted into a body cavity.
• endoscopes use a daylight channel, i.e. the observer sees all finding at the wavelength of naturally occurring light.
• newer endoscopes have the ability to utilize several channels, i.e. a daylight channel and one or more additional channels at other light wavelengths. These additional channels are used to monitor either naturally occurring fluorescence or fluorescence of a dye that was either injected into the body or sprayed onto the body cavity surface.
• One of the possible channels is in the NIR (near infrared) area.
• the advantage of the NIR area is that the light absorption in the NIR area (usually 600-800 nm) is minimal, and fluorescence can be detected at a depth of a few millimeters to nearly a centimeter beneath the surface of the body cavity. It is believed that this has advantages to detect tumors and lymph node metastases in organs such as colon and lung.
• the invention generally relates to phospholipid ether (PLE) compounds, compositions comprising these compounds, and the use of the compounds and/or compositions in diagnosis of various malignancies.
• PLE phospholipid ether
• the present invention relates to phospholipid fluorescent compounds according to formulas (I)-(VI):
• n is an integer between 7 and 23; Y is H, Me or Et; Z is a fluorophore; and X is selected from the group consisting of
• Z is selected from the following:
• R is selected from the group consisting of H, Me, Et, Br and I.
• Q is selected from the group consisting of N, CH, C-Me, C-Et, C- CF 3 , C-Ph
• R j 1 is selected from the group consisting of
• L is selected from the group consisting of O, S, NH and NMe
• R 2 is selected from the group consisting of H, Me, and Et
• R 3 is selected from the group consisting of H, OMe, OEt, and
• R 4 is selected from the group consisting of H, Me, Et, Ph or p- methoxy-phenyl; and m is an integer from 1 to 5.
• R is selected from the group consisting of H, Me, Et, Br and R 6 is selected from the group consisting of H, Me, Et, p- methoxy-phenyl, p-( ⁇ /, ⁇ /-dimethylam ⁇ no)-phenyl and
• R7 wherein R • >7 ; is, selected from the group consisting of H 1 Me, OMe, and Me 2 N
• n is an integer between 7 and 23
• m is an integer between 0 and 4
• X is selected from the group consisting of O, S, CMe 2 , and
• Y is selected from the group consisting of Me, Et, Pr, ⁇ -Pr and
• n is an integer between O and 4.
• Y is selected from the group consisting of Me, Et, Pr and i-Pr;
• R 8 is selected from the group consisting of
• n is an integer between 7 and 23; and Z is selected from the group consisting of
• n is an integer between 7 and 23
• R 9 is selected from the group consisting of Me, Et and
• Z is selected from the group consisting of
• the invention relates to a compound having a formula: OPOCH 2 CH 2 NMe 3
• the invention also generally relates to compositions comprising the compounds of the present invention
• the invention also generally relates to various methods of using the compounds of the present invention, including, but not limited to, endoscopic determination of the presence of internal malignancy, visual and/or microscopically added determination of the presence of malignant lesions on the skin, aiding in the selection of biopsy tissues in internal and skin malignancies, determination of the presence of internal and/or skin malignancies during surgeries to aid the complete biopsy and/or surgical resection of said malignancies
• FIG 1a depicts skin melanoma (A375) cells after 24 hour incubation with
• FIG 1 b depicts normal skin (704sk) cells after 24 hour incubation with
• FIG 2a depicts skin melanoma (A375) cells after O 5 hour incubation with
• FIG 2b depicts skin melanoma (A375) cells after 1 hour incubation with
• FIG 2c depicts colorectal adenocarcinoma (HCT-1 16) cells after 24 hour incubation with CLR1501 ,
• FIG 2d depicts uterine carcinoma (MES SA/Dx5) cells after 24 hour incubation with CLR1501 ,
• FIG 2e depicts pancreatic carcinoma (Mia Paca-2) cells after 24 hour incubation with CLR1501
• FIG. 2f depicts pancreatic carcinoma (Panc-1) cells after 24 hour incubation with CLR1501 ;
• FIG. 2g depicts ovarian adenocarcinoma (Ovcar-3) cells after 24 hour incubation with CLR1501 ;
• FIG. 2h depicts ovarian adenocarcinoma (Ovcar-3) cells after 24 hour incubation with CLR1501 ;
• FIG. 2i depicts glioblastoma (U-87MG) cells after 24 hour incubation with
• FIG. 2j depicts normal fibroblast (NFA) cells after 24 hour incubation with
• FIG. 2k depicts clear cell carcinoma (Caki 2) cells after 24 hour incubation with CLR1501 ;
• FIG. 2I depicts prostate adenocarcinoma (PC3) cells after 24 hour incubation with CLR1501 ;
• FIG. 3 depicts glioblastoma (U-87MG) cells after 48 hour incubation with
• FIG. 4 depicts co-localization of CLR1501 with Normal Fibroblast (NFA) and prostate adenocarcinoma (PC3) cells;
• NFA Normal Fibroblast
• PC3 prostate adenocarcinoma
• FIG. 5 depicts co-localization of CLR1501 with Normal Fibroblast (NFA) and clear cell carcinoma (Caki 2) cells;
• FIG. 6 depicts an image of an athymic nude mice inoculated with pancreatic carcinoma and injected with a composition comprising CLR1501 ;
• FIG. 7 depicts images of excised tumors of mice injected with CLR1501 ;
• FIG. 8 depicts tumor co-localization of CLR1502 in human colorectal carcinoma (HCT- 116) tumor bearing mouse;
• FIG. 9 depicts tumor co-localization of CLR1501 in de-skinned pancreatic carcinoma (Panc-1 ) tumor bearing mouse.
• FIG. 10 depicts tumor co-localization of CLR1501 in de-skinned pancreatic carcinoma (Panc-1) tumor bearing mouse as shown using Kodak X-Sight 761
• alkyl includes straight chained and branched hydrocarbon groups containing the indicated number of carbon atoms, typically methyl, ethyl, and straight chain and branched propyl and butyl groups
• alkyl also encompasses cycloalkyl, i.e , a cyclic C 3 -C 8 hydrocarbon group, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl
• a branched chain isomer, such as "isopropyl,” is specifically referred to
• Me refers to methyl
• Ph refers to phenyl
• i-Pr refers to iso-propyl
• phospholipid ether compound and “phospholipid compound” are used interchangeably for the purposes of the present application
• the present invention generally relates to fluorescent PLE compounds and various methods of their use for malignancy determination and other uses.
• the invention generally refers to phospholipid fluorescent dyes according to formulas (I)-(VI):
• n is an integer between 7 and 23
• Y is H, Me or Et
• Z is a fluorophore
• X is selected from the group consisting of
• Z is selected from the following
• R is selected from the group consisting of H. Me, Et, Br and I.
• Q is selected from the group consisting of N, CH, C-Me, C-Et, C-
• R 1 is selected from the group consisting of
• L is selected from the group consisting of O, S, NH and NMe
• R 2 is selected from the group consisting of H, Me, and Et
• R 3 is selected from the group consisting of H, OMe, OEt, and
• R 4 is selected from the group consisting of H, Me, Et, Ph or p- methoxy-phenyl; and m is an integer from 1 to 5.
• X is selected from the group consisting of O, S, CMe 2 , and
• Y is selected from the group consisting of Me, Et, Pr, i-Pr and
• n is an integer between 0 and 4.
• X is selected from the group consisting of O, S, CMe 2 and
• Y is selected from the group consisting of Me, Et, Pr and i-Pr;
• R 8 is selected from the group consisting of
• n is an integer between 7 and 23; and Z is selected from the group consisting of
• n is an integer between 7 and 23
• R 9 is selected from the group consisting of Me, Et and
• Z is selected from the group consisting of
• the particularly preferred compounds are:
• counterions e g , CI ⁇
• the invention encompasses compounds with and without counterions.
• the fluorescent compounds according to the present invention generally exhibit fluorescence at a wavelength of about 300 nm to about 1000 nm.
• the first wavelength is about 400 nm to about 900 nm.
• the second wavelength is about 400 nm to 1 100 nm
• the present invention encompasses the compounds in any racemic, optically-active, polymorphic, or stereroisomeric forms, or mixtures thereof.
• the fluorescent phospholipid compounds may include pure (R)- ⁇ somers In another embodiment the fluorescent phospholipid compounds may include pure (S)- ⁇ somers In another embodiment the fluorescent phospholipid compounds may include a mixture of the (R) and the (S) isomers In another embodiment, the fluorescent phospholipid compounds may include a racemic mixture comprising both (R) and (S) isomers It is well known in the art how to prepare optically-active forms (for example, by resolution of the racemtc form by recrystallization techniques, by synthesis from optically-active starting mate ⁇ ais by chiral synthesis, or by chromatographic separation using a chiral stationary phase)
• the compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms, e.g , hemi-hydrate.
• solvated forms including hydrated forms, e.g , hemi-hydrate.
• pharmaceutically acceptable solvents such as water, ethanol, and the like are equivalent to the unsolvated forms for the purposes of the invention
• the compounds of the invention are ambiphilic.
• Certain compounds of the invention also form pharmaceutically acceptable salts, e g., acid addition salts.
• the nitrogen atoms may form salts with acids.
• suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, furma ⁇ c, succinic, ascorbic, maleic, methanesulfonic and other mineral carboxylic acids well known to those in the art
• the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner
• the free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous hydroxide potassium carbonate, ammonia, and sodium bicarbonate
• the free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid salts are equivalent to their respective free base forms for purposes of the invention (See, for example
• Suitable pharmaceutically acceptable salts of the compounds of this indention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid SLch as hydrochloric a ⁇ d, sulfuric acid methanesulfonic acid fumaric acid maleic acid, succinic acid, acetic acid benzoic acid, oxalic acid ct ⁇ c acid tarta ⁇ c acid carbonic acid or phosphoric acid
• suitable pharmaceutically acceptable salts thereof may include aikali metal salts e g sodsum or potassium salts alkaline earth metal salts e g calcium or magnesium salts and salts formed with suitable organic Iigands e g quaternary ammonium salts
• the compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids
• pharmaceutically acceptable salt means those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio
• Pharmaceutically acceptable salts are well-known in the art For example, S M Berge et al describe pharmaceutically acceptable salts in detail in J Pharmaceutical Sciences, 1977, 66 1 et seq
• the salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid
• Representative acid addition salts include, but are not limited to acetate adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate glycerophosphat
• Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid- containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine
• Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, t ⁇ methylammonium, t ⁇ ethylammonium, diethylammonium, and ethylammonium among others
• Other representative organic amines useful for the formation of base addition salts include ethylenediamme, ethanolamine,
• the invention also includes N-oxides of the amino substituents of the compounds described herein
• Pharmaceutically acceptable salts can also be prepared from the phenolic compounds by treatment with inorganic bases for example sodium hydroxide
• esters of the phenolic compounds can be made with aliphatic and aromatic carboxylic acids for example acetic acid ana benzosc acid esters
• a “dsagnostically efrectve ap-ouV 1" means an amount of a compound that when administered to a subject foi screening for tumors is s ⁇ ff'cient to provide a detectable distinction between a benign sti ucture and a malignant tumor
• the “diagnostically effective amount will vary depending on the compound the condition to be detected the seventy or the condition the age and relative health of the subject the route and form of administration the judgment of the attending medical or veterinary practitioner and other factors
• a compound of the present invention is administered to a subject in a diagnosticaily effective amount
• a compound of the present invention can be administered alone or as part of a pharmaceutically acceptable composition
• a compound or composition can be administered all at once, as for example by a bolus injection multiple times such as by a series of tablets 01 delivered substantially uniformly over a period of time as for example using transdermal delivery It is aiso noted that the dose of the compound can be varied over time
• a compound of the present invention can be administered using an immediate release formulation a controlled release formulation, or combinations thereof
• the term "controlled release" includes sustained release, delayed release, and combinations thereof
• a fluorescent phospholipid compound of the present invention is comb ned with a pharmaceutically acceptable carrier to produce a pharmaceutical preparation for parenteral administration
• pharmaceutically acceptable means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use
• pharmaceutically acceptable salts or “prodrugs” includes the salts and prodrugs of compounds that are, within the scope of sound medical judgment, suitaoie for use with subjects without undue toxicity, irritation, allergic response and the like commensurate with a reasonable benefit/risk ratio and effective for their intended use as well as the zwittenonic forms where possible, of the compounds
• contacting means that the fluorescent phospholipid compound used in the present invention is introduced to a sample containing cells or tissue in a test tube, flask, tissue culture, chip, array, plate microplate, capillary, or the like, and incubated at a temperature and time sufficient to permit binding of the fluorescent phospholipid compound to a receptor or intercalation into a membrane
• Methods for contacting the samples with the fluorescent phospholipid compound or other specific binding components are known to those skilled in the art and may be selected depending on the type of assay protocol to be run Incubation methods are also standard and are known to those skilled in the art
• the term "contacting” means that the fluorescent phospholipid compound used in the present invention is introduced into a patient receiving treatment and the compound is allowed to come in contact in vivo
• the term “contacting” means that the fluorescent phospholipid compound used in the present invention is introduced into a patient requiring screening for tumors and the compound is allowed to come in contact in vivo
• the invention also generally relates to compositions comprising the compounds of the present invention
• composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from a combination of the specified ingredients in the specified amounts
• compositions of the present invention may be prepared as a single unit dose or as a plurality of single unit doses
• a "unit dose” means a discrete amount of the composition comprising a predetermined amount of the active ingredient The amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a patient or a fraction thereof
• pharmaceutical composition means therapeutically effective amounts of the tumor-specific phospholipid ether analog together with suitable diluents preservatives solubilizers, emulsifiers, and adjuvants collectively “pharmaceutica ⁇ y-acceptable carriers "
• effective amount and “diagnostically effective amount” refer to the quantify of active agent sufficient to yield a ⁇ esired effect without undue adverse side effects such as toxicity irritation or al'ergic response
• the specific "effective amount” will vary with such factors as the particu'ar condition being diagnosed the physical condition of the subject the species of the subject, the nature of concurrent therapy (if any) and the specific formulations employed and the structure of the compounds or its derivatives The optimum effective amounts can be readily determined by one of ordinary skill in the art with routine experimentation
• compositions of the present invention may be liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e g , T ⁇ s-HCI, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e g , Tween 20TM, Tween 80TM, Pluronic F68TM, bile acid salts), solubilizing agents (e g , glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e g , ThimerosalTM, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as poly
• compositions of the present invention comprise a compound of the present invention, polysorbate, ethanol. and saline.
• compositions coated with polymers e.g., poloxamers or poloxamines
• Other embodiments of the compositions incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including topical, parenteral, pulmonary, nasal and oral.
• the pharmaceutical composition is administered parenterally, paracartcerally, transmucosaliy, tansdermally, intramuscularly, intravenously, intraclermally. subcutaneousiy, intraperitoneal, intraventricular ⁇ , intracranially and intratumoraily.
• pharmaceutically acceptable carriers include, but are not limited to, 0 01-0. f M and preferably 0.05M phosphate buffer or 0 9% saline
• pharmaceutically acceptable earners may be aqueous or non-aqueous solutions, suspensions, and emuisions
• non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable o-is such as olive oi ⁇ . and injectable organic esters such as ethyl oleate
• Aqueous earners include water alcoholic/ ⁇ qu ⁇ ous solutions emulsions or suspensions including saline and buffered media
• Parenteral vehicles include sodium chloride solution Ringer's dextrose dextrose and sodium chloride lactated Ringer's and fixed oils
• Intravenous vehicles include fluid and nutrient replenishers electrolyte replenishers such as those based on Rsnger's dextrose and tne like
• Preservatives and other additives may also be present such as, for example antimicrobials, antioxidants collating agents inert gases and the like
• Controlled or sustained release compositions according to the invention include formulation in lipophilic depots (e g fatty acids waxes oils) Also comprehended by the invention are particulate compositions coated with polyme r s (e g poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, Iigands or antigens or coupled to Iigands of tissue-specific receptors.
• polyme r s e g poloxamers or poloxamines
• Other embodiments of the compositions according to the invention incorporate particulate forms, protective coatings protease inhibitors or permeation enhancers for various routes of administration, including parenteral pulmonary, nasal and oral
• the pharmaceutical preparations administrable by the invention can be prepared by known dissolving mixing, granulating or tablet-forming processes
• the tumor-specific phospholipid ether analogs or their physiologically tolerated derivatives such as salts esters N- oxides, and the like are mixed with additives customary for te purpose, such as vehicles stabilizers, or inert diluents and converted by customary methods into suitable forms for administration sucn as tablets coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions
• suitable inert vehicles are conventional tablet bases such as lactose sucrose or cornstarch in combination with binders such as acacia, cornstarch gelatin with disintegrating agents such as cornstarch, potato starch, alginic acid, or with a lubricant such as stearic acid or magnesium stearate
• suitable oily vehicles or solvents are vegetable or animal oils such as sunflower oil or fssh-liver oi! Preparations can be effected botn as dry and as wet granules
• parenteral administration subcutaneous intravenous, intra-arteriai, or intramuscular injection
• the tumor-specific phospholipid ether analogs or their physiologically tolerated derivatives such as salts esters, N-ox ⁇ des, and the like are converted into a solution, suspension or expulsion, if desired with the suDstances customary and suitable for this purpose for example solubilizers or other auxiliaries
• sterile liquids such as water and oils with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants
• Illustrative oils are those of petroleum, animal vegetable or synthetic origin, for example peanut oil, soybean oil, or mineral oil
• saline aqueous dextrose and reiated sugar soiuxions and glycols such as propylene glycols or polyethylene glycol are
• compositions wmch contain an active component
• Such compositions may be prepared as aerosols delivered to the nasopharynx or as injectabtes, either as liquid solutions or suspensions, however, solid forms suitable for solution in or suspension in, liquid prior to injection can also be prepared
• the preparation can also be emulsified Active therapeutic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient Suitable ex ⁇ pients are, for example, water saline, dextrose glycerol ethane! or the like or any combination thereof
• composition can contain minor amounts of auxiliary substances such as wetting or emu ⁇ sifysng agents pH buffering agents which enhance the effectiveness of the active ingredient
• the compounds of the present invention may be used in a variety of diagnostic and therapeutic methods
• the compounds may administered to the patient via either the enteral or parenteral routes ( ⁇ e , orally or via IV) for the endoscopic determination of the presence of internal malignancy
• enteral or parenteral routes ⁇ e , orally or via IV
• examples include, but are not limited to, endoscopic diagnosis of malignancy in the colon, rectum, small bowel, esophagus, stomach, duodenum, uterus, pancreas and common bile duct, bronchi, esophagus, mouth, sinus, lung, bladder, kidney, abdominal cavity or thoracic (chest) cavity
• the invention provides a method for endoscopically distinguishing a benign tissue from a malignant tissue in a selected region by using an endoscope having at least two wavelength in a patient comprising the steps of (a) administering a fluorescently labeled compound to the patient, (b) using a first technique to produce a visualization of the anatomy of the selected region using the first wavelength of an endoscope, (c) using a second technique to produce a visualization of the distribution of fluorescence produced by the fluorescently labeled compound, and (d) comparing the visualization of the anatomy of the selected region by the first wavelength to the visualization of the distribution of fluorescence by the second wavelength produced by the fluorescently labeled compound thereby distinguishing a benign tissue from malignant tissue
• the selected region is the gastro-intestinal tract and the respiratory tract
• a fluorescent phospholipid compound is injected intravenously a few hours before performing endoscopic examinations, more preferably from about 1 hour to about 4 hours
• the compounds may be used to aid in the selection of biopsy tissues in the above-listed internal malignancies
• the compounds may be administered to the patient via either the enteral or parenteral routes or via topical application for the visual and/or microscopically aided determination of the presence of malignant lesions on the skin Examples include, but are not limited to, differentiating between benign and malignant lesions on the skin
• the compounds may be used to aid in the selection of biopsy tissues in the above-listed skin malignancies
• the invention generally relates to a A method of selecting a biopsy tissue in a region suspected of having a malignancy comprising (a) administering to a patient a fluorescent phospholipid ether compound; (b) using a first technique to produce a visualization of the anatomy of said region suspected of having said malignancy using the first wavelength of an endoscope; (c) using a second technique to produce a visualization of the distribution of fluorescence produced by the fluorescent phospholipid ether compound; and (d) comparing the visualization of the anatomy of said region suspected of having said malignancy by the first wavelength to the visualization of the distribution of fluorescence by the second wavelength produced by the fluorescent phospholipid ether compound thereby distinguishing a benign tissue from malignant tissue and allowing to choose the biopsy tissue.
• the compounds may be used to aid in the determination of malignant tissue margins during operative resection or Mohs surgery of such lesion.
• the compounds may be administered to the patient via either the enteral or parenteral routes (i.e. orally or IV) for the visual and or microscopic-aided determination of the presence of malignant tissue at the borders of known malignancies during surgery.
• enteral or parenteral routes i.e. orally or IV
• examples include, but are not limited to, the intraoperative determination of the borders of a malignancy to aid the complete biopsy and/or surgical resection of said malignancy.
• the compounds may be used to determine the presence of residual malignant stem cells in a pathological specimen that has been excised from the body of the patient and/or to determine the presence of residual cancer stem cells in situ in a patient.
• the invention provides a method of determining the presence of residual malignant stem cells in a patient undergoing cancer therapy comprising (a) administering to a patient undergoing said cancer therapy the fluorescent phospholipid compound according to any of claims 1 through 4; (b) visualizing the tissue that was determined to be malignant prior to said cancer therapy; and (c) assessing accumulation of the fluorescent phospholipid compound in said tissue, wherein an accumulation of said fluorescent phospholipid compound in said tissue indicates a possible presence of residual malignant stem cells.
• the invention provides a method of determining the presence of residual malignant stem cells in a patient undergoing cancer therapy comprising (a) excising a pathological specimen from a patient undergoing said cancer therapy; b) incubating said pathological specimen with the fluorescent phospholipid compound according to any of claims 1 through 4; and (c) visualizing the distribution of said fluorescent phospholipid compound in said pathological specimen: wherein an accumulation of said fluorescent phospholipid compound in said specimen indicates a possible presence of residual malignant stem cells.
• the provided compounds may be used for tumor therapy response monitoring.
• the invention provides a method of monitoring response to a tumor therapy comprising (a) administering to a patient prior to said tumor therapy the fluorescent phospholipid compound according to any of claims 1 through 4; (b) providing said tumor therapy; (c) providing the fluorescent phospholipid compound according to any of claims 1 through 4 after the tumor therapy; and (d) assessing difference in accumulation of the fluorescent phospholipid compound from step (a) and step (c), wherein a greater accumulation of the phospholipid compound in step (a) versus lesser accumulation in step (c) indicates a positive response to the treatment and/or an effective treatment methodology.
• CLR1501 The synthesis of CLR1501 was performed using Liebeskind-Srogl cross-coupling reaction (Liebeskind LS, Srogl J. Org. Lett., 2002, 4, 979-981 ) of 18-[p-(dihydroxyboryl)-phenyl]-octadecyl phosphocholine 2 with 8- thiomethyl-BODIPY 1 according to the published procedure (Pena-Cabrera E. et al. Org. Lett, 2007, 9, 3985-3988, J. Org. Chem., 2009, 74, 2053-2058).
• Pd2(dba) 3 tris-(dibenzylideneacetone) dipalladium (0)
• TFP tri-(2-furyl) phosphine
• CLR1502 can also be referred to as IR-775-CLR1501 conjugate.
• IR- 775 is a commercial dye made by Sigma-Aldrich®.
• Scheme 1 Synthesis of BODIPY-modified octadecyl phosphocholine without a phenyl ring between BODIPY fragment and alkyl chain is shown in Scheme 1 Synthesis can be performed according to the literature reference (C Peters et al J Org Chem , 2007, 72, 1842-1845) The synthesis is started from a long- chain acid chloride 3 which is converted into the dipyrromethene by reaction with 2,5-d ⁇ methylpyrrole This compound is used for the introduction of the BF 2 bridge, providing the BODIPY intermediate 4 which is converted into the phosphochoiine 5
• Scheme 4 provides an example of the synthesis of heteroaryl-fused BODIPY alkyl phospholipid 16.
• Hetreoaryl-fused BODIPY dyes have been described in the literature (Umezawa K, Matsui A, Nakamura Y, Citterio D, Suzuki K. Chem. Eur. J., 2009, 15, 1096-1 106; Umezawa K, Nakamura H, Makino H, Citterio D, Suzuki K. J. Am. Chem. Soc, 2008, 130, 1550-1551 ), and they exhibit high extinction coefficients and high quantum yields in the far- red and near-IR regions of the spectrum.
• BODIPY intermediate 15 is based on the procedures provided in the literature (Umezawa K, Matsui A, Nakamura Y, Citterio D, Suzuki K. Chem. Eur. J., 2009, 15, 1096-1 106; Goud T.V., Tutar A., Biellman J. F. Tetrahedron, 2006, 62, 5084-5091 ).
• the synthesis of fluorescent alkyl phosphocholine 16 is performed using Liebeskind-Srogl cross-coupling reaction (Liebeskind LS, Srogl J. Org.
• Scheme 6 shows the synthesis of rigid cyanine-based fluorescent alkyl phospholipid 20. Synthesis of compound 19 is referenced in the literature (Goncalves MS. Chem. Rev., 2009, 109, 190-212). Palladium-catalyzed cross-coupling of 19 with 18-[p-(dihydroxyboryl)-phenyl]-octadecyl phosphocholine 2 provides fluorescent phospholipid 20.
• Scheme 8 Another example shown in Scheme 8 includes mono-alkyl phosphocholine derivative of lndocyanine Green 24.
• CLR1501 was introduced into skin melanoma (A375) and normal skin (704sk) cells, purchased from ATCC. Both cells were maintained at 37°C in DMEM media supplemented with 10% FBS and 5% CO 2 . Before imaging, the cells were removed from flasks with 0.25% trypsin and were allowed to grow overnight on the slides (Ibidi, microslides Vl flat, Catalog No: 80626). The next day, the media was gently replaced with Phosphate Buffered Saline (PBS) and the cells were incubated with 7.5 ⁇ M of CLR1501 on DMEM media for 24 hours. CRL1501 was formulated with 0.4% of Polysorbate 20, 2% of ethanol and saline. After washing thoroughly with PBS, the cells were imaged using Bio-Rad Radiance 2100 MP Rainbow with 1 second exposure time. Results
• FIGs 1a and 1 b demonstrate, in 704sk cells, the CLR 1501 appeared to be transported to the lysosomes where it was degraded (FIG 1 b) A375 cells showed internalization of CLR1501 into numerous fluorescent vesicles that are scattered throughout the cytoplasm (FIG 1 a)
• FIGs 2a and 2b demonstrate early time uptake profiles of CLR1501 in A375 cells half an hour (Fig 2a) and one hour (Fig 2b) after incubation
• Fig 2a demonstrates, after half an hour, the signals are thin and limited at the plasma membrane
• Fig 2b demonstrates, within one hour, the signals are not concentrated solely in the plasma membrane intracellular structures are also observed
• Table 1 illustrates intensity of signal emitted by CLR1501 in cancerous cell lines versus normal cells TABLE 1
• FIG. 2c demonstrates the results for colorectal adenocarcinoma cell line (HCT-1 16);
• FIG. 2d demonstrates the results for uterine sarcoma cell line (MES SA/DX-5);
• FIG. 2e demonstrates the results for pancreatic carcinoma cell line (Mia Paca-2);
• FIG. 2f demonstrates the results for pancreatic carcinoma cell line (Panc-1 );
• FIG. 2g demonstrates the results for ovarian adenocarcinoma cell line (Ovcar-3);
• FIG. 2h demonstrates the results for ovarian adenocarcinoma cell line (Ovcar-3);
• FIG. 2i demonstrates the results for glioblastoma cell line (U-87MG);
• FIG. 2j demonstrates the results for normal fibroblast cell line (NFA).
• FIG. 2k demonstrates the results for clear cell carcinoma cell line (Caki-2).
• FIG. 2I demonstrates the results for prostate adenocarcinoma cell line (PC3).
• Figures 2c-2i and 2k-2l demonstrate a significant uptake of CLR1501 in all of these cell lines. It is known that structurally related radioiodinated alkyl phosphocholine analog NM404 (18-p-( ⁇ odophenyl)-octadecyl phosphocholine) undergoes prolonged (> 80 days in mouse models) and selective retention in a wide variety (37 out of 37) of xenograft and spontaneous primary and metastatic human and rodent tumor models. These experiments demonstrate that CLR1501 , a fluorescent analog of NM404, displays a similar selective uptake and retention in tumor cell lines in vitro
• FIG 3 demonstrates the results of an incubation of glioblastoma cells (U87MG) with CLR1501 for 48 hours in Eagle MEM media at 37° C with 10% FBS and 5% CO 2 .
• the following co-stained dyes were used' Hoechst 33342 (1 ⁇ g/ml_) (nucleus; blue color) Mitotracker (25nM) (mitochondria, red color) and Blue-White DPX (10OnM) (Endoplasmic Reticulum (ER), blue color) were diluted in PBS and added to the cells for 15 minutes The cells were washed with PBS and imaged with Bio-Rad Radiance 2100 MP Rainbow.
• CLR1501 mostly accumulated in cytoplasm of the cells.
• the nucleus appeared blue while the red signals showed the distribution of mitochondria (colors are not reproduced on the photographs submitted with the PCT application).
• CLR1501 was co-localized with mitochondria and ER.
• the cyan signals (dark oval-shaped spots in FIG 3) mostly distributed outside the nucleus near the nuclear membrane
• FIG 4 demonstrates the results of co-cultu ⁇ ng NFA cells and PC3 cells, incubating them with CLR1501 and co-staining them with nucleus stain and mitochondria marker
• NFA and PC3 cell lines were co-cultured overnight on micro slide Vl (Ibidi, Verona, Wl). The next day, the cells were incubated with 5 ⁇ M of CLR1501 for 24 hours at 37 0 C in complete media The next day after washing with PBS, the cells were co-stained with nucleus stain (Hoechst 33342) and mitochondria marker (Mitotracker), (Invitrogen, Carlsbad, CA).
• CLR1501 was excited and detected using Alexa-Fluor 488 filter, while nucleus stain and mitochondria stain were excited and detected using DAPI filter and Texas-Red filter, respectively.
• CLR1501 was not co-localized with nucleus in both normal and tumor cell lines
• CLR1501 was co- localized with mitochondria in PC3 cell line but not with NFA
• FIG 5 demonstrates the results of co-culturing NFA cells and Cak ⁇ -2 cells, incubating them with CLR1501 and co-staining them with nucleus stain and lysosome marker
• NFA and Cak ⁇ -2 cell lines were co-cultured overnight on micro slide Vl (Ibidi, Verona, Wl) The next day, the cells were incubated with 5 ⁇ M of CLR1501 for 24 hours at 37 0 C in complete media. The next day after washing with PBS, the cells were co-stained with nucleus stain (Hoechst 33342) and lysosome marker (Lyso-tracker), (Invitrogen, Carlsbad, CA). The cells were observed using Nikon A1 R confocal microscope.
• CLR1501 was excited and detected using Alexa-Fluor 488 filter while nucleus stain and lysosome stain were excited and detected using DAPI and Texas- Red filter, respectively CLR 1501 was not co-localized with nucleus in both normal and tumor cell lines However, CLR1501 was co-localized with lysosome in Caki-2 cell line but minimally with NFA
• the inventors conducted in vivo studies of CLR1501 and CLR1502 distribution in athymic nude mice.
• Athymic nude mice Hsd Athymic Nude-Fox1 nu
• Panc- 1 Pancreatic carcinoma
• the fluorescence images were obtained using a Kodak in-Vivo Multispectral System FX.
• the system provides multispectral tuning of excitation light which is able to separate signals from the dye and from the body autofluorescence. Mice were anesthetized by inhalation of isofluorane. The dyes were excited at 570nm.
• FIG 6 depicts the results of this experiment Green signals show distribution of CLR1501 in tumors (marked with white arrows) The left image shows the mouse was injected 24 hours prior to imaging and the right image shows the mouse that was injected 96 hours prior to imaging Black arrows show de-skinned area where CLR1501 accumulation can be seen in contrast
• mice were orally administered 150 ⁇ l_ of CLR1501 at 6 mg/mL, mixed with 100 ⁇ l_ of oil in water phase emulsion (canola oil / saline) 24 and 96 hours prior to imaging
• FIG 7 demonstrates the images of the excised tumors
• FIG 8 depicts tumor co-localization of CLR1502 in HCT-116 tumor- bearing mouse Athymic nude mouse (CrI, NU-Foxn1 nu ) was purchased from Charles River (Charles River, Portage, Ml) The mouse was inoculated with 2x10 6 HCT-1 16 cells (human colorectal carcinoma) After 8 weeks the mouse was injected with 1 mg of CLR1502 in 0 15 m solution CLR1502 was excited at 780 and emitted at 800 nm The intensity was monitored up to 48 hours using Pearl in vivo imaging system (Li-Cor Bioscience, Lincoln, NE) At the end of 48 hours, organs from mouse were collected and imaged Over time, CLR1502 accumulated in tumor site, while it cleared out from the rest of normal organs, showing that CLR1502 is a tumor-specific imaging agent. The following organs were collected: heart, tumor, spleen, lung; Gl tract (not flushed); skin, kidneys and liver.
• organs were collected: heart
• FIG. 9 depicts tumor co-localization of CLR1502 in de-skinned Panc-1 tumor-bearing mouse.
• Athymic nude mouse (CrI, NU-Foxn1 ⁇ u ) was purchased from Charles River (Charles River, Portage, Ml). The mouse was inoculated with 1x10 6 Panc-1 cells (human pancreatic carcinoma). After 8 weeks, the mouse was injected with 1 mg of CLR1501 in 0.15 ml_ solution. CLR1501 was excited at 480 and emitted at 520 nm. The intensity was monitored at 24 and 96 hours using Kodak in vivo imaging system (Carestream Health, Woodbridge, CT).
• CLR1501 Over time, CLR1501 accumulated in tumor site, while it cleared out from the rest of normal organs. Skins surround tumors were removed to provide contrast signal from CLR1501. In this animal model, skin produces autofiuorescence signai which overlaps with excitation and emission wavelengths of CLR1501.
• FIG. 10 depicts tumor co-localization of CLR1501 in athymic nude mouse.
• Athymic nude mouse (CrI, NU-Foxn1 nu ) was purchased from Charles River (Charles River, Portage, Ml). The mouse was inoculated with 1x10 6 Panc-1 cells (human pancreatic carcinoma) which were incubated with CLR1501 or Kodak X-Sight 761 or both CLR1501 and Kodak X-Sight 761 for 4 hours. The celis were harvested and inoculated in different spots. The signals from each dye were obtained using Kodak in vivo imaging system (Carestream Health, Woodbridge, CT). CLR1501 was excited at 480 and emitted at 520 nm while the Kodak X-Sight was excited at 750 and emitted at 830 nm.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Endoscopes (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (5)

Applications Claiming Priority (10)

Related Parent Applications (1)

Related Child Applications (2)

Publications (1)

Family

ID=43085298

Family Applications (1)

Country Status (5)

Cited By (7)

Families Citing this family (9)

Citations (4)

Family Cites Families (28)

• 2010
  • 2010-05-11 ES ES10775385.7T patent/ES2549459T3/es active Active
  • 2010-05-11 WO PCT/US2010/034361 patent/WO2010132428A1/en not_active Ceased
  • 2010-05-11 EP EP10775385.7A patent/EP2429591B1/en active Active
  • 2010-05-11 JP JP2012510929A patent/JP5702366B2/ja active Active
• 2014
  • 2014-09-10 JP JP2014183841A patent/JP6006271B2/ja active Active
  • 2014-09-23 US US14/493,489 patent/US9616140B2/en active Active
• 2015
  • 2015-05-13 JP JP2015098391A patent/JP6073961B2/ja active Active
• 2016
  • 2016-04-27 JP JP2016089336A patent/JP2016193907A/ja active Pending

Patent Citations (4)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events